Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes

Elizabeth L Eby,1 Kate Van Brunt,2 Cynthia Brusko,3 Bradley Curtis,4 Maureen J Lage5 1Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis IN USA; 2Eli Lilly and Co., Windlesham, UK; 3Lilly USA, LLC, Indianapolis, IN, USA; 4Eli Lilly a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eby EL, Van Brunt K, Brusko C, Curtis B, Lage MJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	insulin diabetes costs resource utilization adherence hypoglycemia Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/3b00f7e19d5c4ce8b901e842577cae8b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3b00f7e19d5c4ce8b901e842577cae8b
record_format	dspace
spelling	oai:doaj.org-article:3b00f7e19d5c4ce8b901e842577cae8b2021-12-02T02:10:00ZDosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes1178-1998https://doaj.org/article/3b00f7e19d5c4ce8b901e842577cae8b2015-06-01T00:00:00Zhttps://www.dovepress.com/dosing-of-u-100-insulin-and-associated-outcomes-among-medicare-enrolle-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Elizabeth L Eby,1 Kate Van Brunt,2 Cynthia Brusko,3 Bradley Curtis,4 Maureen J Lage5 1Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis IN USA; 2Eli Lilly and Co., Windlesham, UK; 3Lilly USA, LLC, Indianapolis, IN, USA; 4Eli Lilly and Co., Indianapolis, IN, USA; 5HealthMetrics Outcomes Research, LLC, Bonita Springs, FL, USA Objective: To examine costs, resource utilization, adherence, and hypoglycemic events among various doses of U-100 insulin regimens among elderly patients (age ≥65 years) diagnosed with diabetes.Methods: Truven Health Analytics Medicare databases from January 1, 2008 through December 31, 2011 were utilized. General linear models with a gamma distribution and log link were used to examine costs, while logistic and negative binomial regressions were used to examine resource utilization and hypoglycemic events. Analyses controlled for patient characteristics, pre-period comorbidities, general health, and use of antidiabetic medications as well as index dose of insulin.Results: All-cause inpatient, emergency room, and outpatients costs, as well as diabetes-related inpatient costs, were highest among individuals who were treated with an index dose of 10–100 units/day followed by >300 units/day, while drug costs and total costs generally increased as index dosage increased. Resource utilization generally followed the same pattern as costs, with number of office visits increasing as the dose increased and the highest hospital length of stay, number of hospitalizations, number of emergency room visits, and number of diabetes-related hospitalizations were generally highest among those in the lowest and highest index dose cohorts. Compared to patients who initiated with an index dose of 10–100 units/day, all other patients were significantly less likely to achieve an adherence threshold of 80% based upon index dose range, and while those with an index dose of >100–150 units/day were significantly more likely to experience a hypoglycemic event.Conclusion: These results suggest that, for elderly individuals with diabetes, there is a higher patient burden among those who receive the lowest and highest insulin doses. Keywords: insulin, diabetes, costs, resource utilization, adherence, hypoglycemia Eby ELVan Brunt KBrusko CCurtis BLage MJDove Medical Pressarticleinsulindiabetescostsresource utilizationadherencehypoglycemiaGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 10, Pp 991-1001 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	insulin diabetes costs resource utilization adherence hypoglycemia Geriatrics RC952-954.6
spellingShingle	insulin diabetes costs resource utilization adherence hypoglycemia Geriatrics RC952-954.6 Eby EL Van Brunt K Brusko C Curtis B Lage MJ Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
description	Elizabeth L Eby,1 Kate Van Brunt,2 Cynthia Brusko,3 Bradley Curtis,4 Maureen J Lage5 1Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis IN USA; 2Eli Lilly and Co., Windlesham, UK; 3Lilly USA, LLC, Indianapolis, IN, USA; 4Eli Lilly and Co., Indianapolis, IN, USA; 5HealthMetrics Outcomes Research, LLC, Bonita Springs, FL, USA Objective: To examine costs, resource utilization, adherence, and hypoglycemic events among various doses of U-100 insulin regimens among elderly patients (age ≥65 years) diagnosed with diabetes.Methods: Truven Health Analytics Medicare databases from January 1, 2008 through December 31, 2011 were utilized. General linear models with a gamma distribution and log link were used to examine costs, while logistic and negative binomial regressions were used to examine resource utilization and hypoglycemic events. Analyses controlled for patient characteristics, pre-period comorbidities, general health, and use of antidiabetic medications as well as index dose of insulin.Results: All-cause inpatient, emergency room, and outpatients costs, as well as diabetes-related inpatient costs, were highest among individuals who were treated with an index dose of 10–100 units/day followed by >300 units/day, while drug costs and total costs generally increased as index dosage increased. Resource utilization generally followed the same pattern as costs, with number of office visits increasing as the dose increased and the highest hospital length of stay, number of hospitalizations, number of emergency room visits, and number of diabetes-related hospitalizations were generally highest among those in the lowest and highest index dose cohorts. Compared to patients who initiated with an index dose of 10–100 units/day, all other patients were significantly less likely to achieve an adherence threshold of 80% based upon index dose range, and while those with an index dose of >100–150 units/day were significantly more likely to experience a hypoglycemic event.Conclusion: These results suggest that, for elderly individuals with diabetes, there is a higher patient burden among those who receive the lowest and highest insulin doses. Keywords: insulin, diabetes, costs, resource utilization, adherence, hypoglycemia
format	article
author	Eby EL Van Brunt K Brusko C Curtis B Lage MJ
author_facet	Eby EL Van Brunt K Brusko C Curtis B Lage MJ
author_sort	Eby EL
title	Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
title_short	Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
title_full	Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
title_fullStr	Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
title_full_unstemmed	Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
title_sort	dosing of u-100 insulin and associated outcomes among medicare enrollees with type 1 or type 2 diabetes
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/3b00f7e19d5c4ce8b901e842577cae8b
work_keys_str_mv	AT ebyel dosingofu100insulinandassociatedoutcomesamongmedicareenrolleeswithtype1ortype2diabetes AT vanbruntk dosingofu100insulinandassociatedoutcomesamongmedicareenrolleeswithtype1ortype2diabetes AT bruskoc dosingofu100insulinandassociatedoutcomesamongmedicareenrolleeswithtype1ortype2diabetes AT curtisb dosingofu100insulinandassociatedoutcomesamongmedicareenrolleeswithtype1ortype2diabetes AT lagemj dosingofu100insulinandassociatedoutcomesamongmedicareenrolleeswithtype1ortype2diabetes
_version_	1718402641904533504

Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes

Ejemplares similares